We found that 17 RTKs, including MET, were significantly upregulated in pancreatic cancer tissues compared with normal pancreatic tissue, suggesting that they are potentially viable therapeutic targets (Fig. 2A and B). The gene discussed is MET; the disease is familial pancreatic carcinoma.